Summary

mRNA Vaccines and Therapeutics Market – Scope of Report
TMR’s report on the global mRNA vaccines and therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global mRNA vaccines and therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mRNA vaccines and therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the mRNA vaccines and therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global mRNA vaccines and therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global mRNA vaccines and therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global mRNA vaccines and therapeutics market.

The report delves into the competitive landscape of the global mRNA vaccines and therapeutics market. Key players operating in the global mRNA vaccines and therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global mRNA vaccines and therapeutics market profiled in this report.

Key Questions Answered in Global mRNA vaccines and therapeutics Market Report
• What is the sales/revenue generated by mRNA vaccines and therapeutics across all regions during the forecast period?
• What are the opportunities in the global mRNA vaccines and therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

mRNA Vaccines and Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global mRNA vaccines and therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global mRNA vaccines and therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global mRNA vaccines and therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global mRNA Vaccines and Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by mRNA Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by mRNA Type, 2020-2034
6.3.1. Nucleoside-modified mRNA
6.3.2. Unmodified mRNA
6.3.3. Self-amplifying mRNA
6.4. Market Attractiveness, by mRNA Type
7. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2020-2034
7.3.1. Prophylactic
7.3.2. Therapeutic
7.3.3. 7.4 Market Attractiveness, by Type
8. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2020-2034
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Rare Genetic Diseases
8.3.4. Others (Respiratory Diseases, etc.)
8.4. Market Attractiveness, by Application
9. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals & Clinics
9.3.2. Biopharmaceutical Companies
9.3.3. Others (Research Organizations, etc.)
9.4. Market Attractiveness, by End-user
10. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America mRNA Vaccines and Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by mRNA Type, 2020-2034
11.2.1. Nucleoside-modified mRNA
11.2.2. Unmodified mRNA
11.2.3. Self-amplifying mRNA
11.3. Market Attractiveness, by mRNA Type
11.4. Market Value Forecast, by Type, 2020-2034
11.4.1. Prophylactic
11.4.2. Therapeutic
11.5. Market Attractiveness, by Type
11.6. Market Value Forecast, by Application, 2020-2034
11.6.1. Infectious Diseases
11.6.2. Oncology
11.6.3. Rare Genetic Diseases
11.6.4. Others (Respiratory Diseases, etc.)
11.7. Market Attractiveness, by Application
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals & Clinics
11.8.2. Biopharmaceutical Companies
11.8.3. Others (Research Organizations, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By mRNA Type
11.11.2. By Type
11.11.3. By Application
11.11.4. By End-user
11.11.5. By Country
12. Europe mRNA Vaccines and Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by mRNA Type, 2020-2034
12.2.1. Nucleoside-modified mRNA
12.2.2. Unmodified mRNA
12.2.3. Self-amplifying mRNA
12.3. Market Attractiveness, by mRNA Type
12.4. Market Value Forecast, by Type, 2020-2034
12.4.1. Prophylactic
12.4.2. Therapeutic
12.5. Market Attractiveness, by Type
12.6. Market Value Forecast, by Application, 2020-2034
12.6.1. Infectious Diseases
12.6.2. Oncology
12.6.3. Rare Genetic Diseases
12.6.4. Others (Respiratory Diseases, etc.)
12.7. Market Attractiveness, by Application
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals & Clinics
12.8.2. Biopharmaceutical Companies
12.8.3. Others (Research Organizations, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By mRNA Type
12.11.2. By Type
12.11.3. By Application
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific mRNA Vaccines and Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by mRNA Type, 2020-2034
13.2.1. Nucleoside-modified mRNA
13.2.2. Unmodified mRNA
13.2.3. Self-amplifying mRNA
13.3. Market Attractiveness, by mRNA Type
13.4. Market Value Forecast, by Type, 2020-2034
13.4.1. Prophylactic
13.4.2. Therapeutic
13.5. Market Attractiveness, by Type
13.6. Market Value Forecast, by Application, 2020-2034
13.6.1. Infectious Diseases
13.6.2. Oncology
13.6.3. Rare Genetic Diseases
13.6.4. Others (Respiratory Diseases, etc.)
13.7. Market Attractiveness, by Application
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals & Clinics
13.8.2. Biopharmaceutical Companies
13.8.3. Others (Research Organizations, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By mRNA Type
13.11.2. By Type
13.11.3. By Application
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America mRNA Vaccines and Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by mRNA Type, 2020-2034
14.2.1. Nucleoside-modified mRNA
14.2.2. Unmodified mRNA
14.2.3. Self-amplifying mRNA
14.3. Market Attractiveness, by mRNA Type
14.4. Market Value Forecast, by Type, 2020-2034
14.4.1. Prophylactic
14.4.2. Therapeutic
14.5. Market Attractiveness, by Type
14.6. Market Value Forecast, by Application, 2020-2034
14.6.1. Infectious Diseases
14.6.2. Oncology
14.6.3. Rare Genetic Diseases
14.6.4. Others (Respiratory Diseases, etc.)
14.7. Market Attractiveness, by Application
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals & Clinics
14.8.2. Biopharmaceutical Companies
14.8.3. Others (Research Organizations, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By mRNA Type
14.11.2. By Type
14.11.3. By Application
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa mRNA Vaccines and Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by mRNA Type, 2020-2034
15.2.1. Nucleoside-modified mRNA
15.2.2. Unmodified mRNA
15.2.3. Self-amplifying mRNA
15.3. Market Attractiveness, by mRNA Type
15.4. Market Value Forecast, by Type, 2020-2034
15.4.1. Prophylactic
15.4.2. Therapeutic
15.5. Market Attractiveness, by Type
15.6. Market Value Forecast, by Application, 2020-2034
15.6.1. Infectious Diseases
15.6.2. Oncology
15.6.3. Rare Genetic Diseases
15.6.4. Others (Respiratory Diseases, etc.)
15.7. Market Attractiveness, by Application
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals & Clinics
15.8.2. Biopharmaceutical Companies
15.8.3. Others (Research Organizations, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By mRNA Type
15.11.2. By Type
15.11.3. By Application
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Moderna, Inc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. BioNTech SE.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. CureVac SE
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Arcturus Therapeutics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Sanofi
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. GSK plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Argos Therapeutics Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ethris
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Pfizer Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. AstraZeneca
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview